Participant profile: Reset Therapeutics

Ross founded Reset Therapeutics in 2008 with Dr. Ronald Evans of the Salk Institute and Drs. Joseph Takahashi and Masashi Yanagisawa from the University of Texas Southwestern Medical Center. Prior to co-founding Reset, Mr. Bersot served as a Managing Director of Bay City Capital, where he focused on investment opportunities in visionary biopharmaceutical and technology companies.

We hope to bring breakthrough treatments to patients in need. Access to the Elsevier Solutions will inform our decision-making process, and hopefully, our chances of developing safe and effective new drugs.

Paul joined Reset Therapeutics as the Head of Drug Discovery at Reset Therapeutics after serving as a Senior Principal Scientist at Pfizer. where he worked in the area of Metabolic Diseases.

Given the fact that Reset is a phenotypic, disease-area agnostic research company it is important to have access to all of the top scientific journals offered by ScienceDirect. In my previous life as chemist I also enjoyed using Reaxys and it’s great to have access to this excellent resource once again. Going forward, I look forward to utilizing Pathway Studio in order to better mine information related to our current mechanisms of action.

Jamie is responsible for coordinating the process of moving Reset’s lead Cryptochrome modulator program from proof of concept to IND submission and early to mid-stage clinical development.

Since having had the opportunity of using Elsevier’s Hive, I can already appreciate the convenience and power of a coordinated set of tools built on Elsevier’s growing dominance. To offer one concrete example, some years ago I spent more time and more emails than I care to admit in the ultimately unsuccessful search for a 1970’s era monograph on a grandfathered therapeutic polymer. In less than five minutes on PharmaPendium in The Hive, I found it.

Tod is currently the biology lead for the orexin program for the treatment of narcolepsy. He made the initial discovery of orexin receptor allosteric modulators at Reset as part of an NIH-funded grant for narcolepsy and he continues to further characterize these molecules.

The immediate access to top scientific journals offered by ScienceDirect is important in maintaining pace for a nimble and cutting-edge research organization.

Melissa is a medicinal chemist with 13 years of experience in the pharmaceutical industry. Before joining Reset Therapeutics, she worked at Gilead, Theravance and MyoKardia, where she contributed to bioactive molecules synthesis and design for treating diseases affecting the liver, heart, lung and intestine.

I used Reaxys to help us design synthetic route more efficiently. I see a great benefit for early-stage companies to partake in The Hive and have access to Pathway Studio, Embase, PharmaPendium, Reaxys, and ScienceDirect. The Hive will definitely help with R&D productivity, efficiency and organization.